KIMBERLY CORNELISON: Open Payments
NPI 1154715662 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$543 in 30 payments from 7 companies in 2025. Trend: 2023 $42 · 2024 $52 · 2025 $543
Food & beverage: $543
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $175 |
| Alkermes, Inc. | 5 | $119 |
| Neurocrine BioSciences, Inc. | 4 | $96 |
| Otsuka America Pharmaceutical, Inc. | 4 | $70 |
| Lundbeck LLC | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
Products named: UZEDY, ARISTADA, INGREZZA, ABILIFY MAINTENA, FANAPT, COBENFY, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across AL — which companies pay providers there.
